. 2012 Aug 22;135(3):715–724. doi: 10.1007/s10549-012-2202-6

Table 2.

Association of nine SNPs identified from previous GWAS with breast cancer risk in Tunisian women

SNP	Gene/locus	Allele^a	Risk allele Frequency (%)		HetOR (95 % CI)	P value	HomOR (95 % CI)	P value	Per risk allele (95 % CI)	P value
SNP	Gene/locus	Allele^a	Case	Control	HetOR (95 % CI)	P value	HomOR (95 % CI)	P value	Per risk allele (95 % CI)	P value
rs1219648	FGFR2	A/G	45.7	38.2	1.60 (1.19–2.16)	0.001	1.70 (1.15–2.51)	0.004	1.36 (1.13–1.65)	0.001
rs2981582	FGFR2	G/A	50.2	39.4	2.00 (1.47–2.73)	0.000004	2.23 (1.51–3.29)	0.00001	1.55 (1.28–1.88)	0.000003
rs8051542	TNRC9^b	C/T	44.5	36.4	1.15 (0.86–1.54)	0.32	2.11 (1.39–3.19)	0.0001	1.40 (1.16–1.69)	0.0004
rs12443621	TNRC9	G/A	46.6	48.2	0.86 (0.63–1.18)	0.34	0.89 (0.61–1.30)	0.53	0.94 (0.78–1.13)	0.49
rs3803662	TNRC9	C/T	45.9	43.5	1.12 (0.83–1.52)	0.45	1.19 (0.82–1.72)	0.34	1.10 (0.91–1.33)	0.3
rs889312	MAP3K1	A/C	35.1	28.9	1.37 (1.03–1.81)	0.02	1.74 (1.08–2.82)	0.01	1.33 (1.09–1.63)	0.003
rs3817198	LSP1	T/C	32.1	28.4	1.15 (0.87–1.52)	0.3	1.45 (0.90–2.34)	0.1	1.19 (0.97–1.46)	0.08
rs13387042	2q35	A/G	41.6	44.8	0.92 (0.68–1.25)	0.5	0.76 (0.52–1.12)	0.15	0.88 (0.73–1.06)	0.16
rs13281615	8q24	A/G	55.2	50.4	1.19 (0.85–1.66)	0.3	1.44 (0.99–2.10)	0.04	1.21 (1.00–1.46)	0.03

CI confidence interval, OR odds ratio, HetOR odds ratio in heterozygote, HomOR odds ratio in homozygote for risk allele (relative to homozygote for non-risk allele)

^aReference allele/risk allele

^bAlso known as TOX3